menu
    • menu
    [{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aquestive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Averitas Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Averitas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Averitas Pharma","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Capsaicin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase III","graph3":"Averitas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Averitas Pharma \/ Grunenthal","highestDevelopmentStatusID":"10","companyTruncated":"Averitas Pharma \/ Grunenthal"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Cognitive Research Corporation","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ozanimod","moa":"S1P receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Celgene Corporation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Celgene Corporation \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ BARDA"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Zambon Group SpA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Safinamide Methanesulfonate","moa":"MAO-B","graph1":"Neurology","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Newron Pharmaceuticals \/ Zambon Group SpA","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pharmaceuticals \/ Zambon Group SpA"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenue Therapeutics \/ Aegis Capital","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Aegis Capital"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zilganersen","moa":"Glial fibrillary acidic protein","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"Zilganersen","moa":"Glial fibrillary acidic protein","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Zilganersen","moa":"Glial fibrillary acidic protein","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Solanezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"||Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Solanezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Solanezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Eisai"},{"orgOrder":0,"company":"Quanterix","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Phase III","graph3":"Quanterix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quanterix \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Quanterix \/ Eli Lilly"},{"orgOrder":0,"company":"Quanterix","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Phase III","graph3":"Quanterix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quanterix \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Quanterix \/ Eli Lilly"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai Inc \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Eisai Inc \/ Biogen"},{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Partnership","leadProduct":"Lecanemab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Frontage Laboratories, Inc \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Frontage Laboratories, Inc \/ Eisai"},{"orgOrder":0,"company":"Genentech","sponsor":"AC Immune","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crenezumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ AC Immune","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ AC Immune"},{"orgOrder":0,"company":"AVANIR PHARMS","sponsor":"Otsuka America Pharmaceutical, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"Deudextromethorphan Hydrobromide","moa":"||MAO","graph1":"Neurology","graph2":"Phase III","graph3":"AVANIR PHARMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AVANIR PHARMS \/ Otsuka America Pharmaceutical, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"AVANIR PHARMS \/ Otsuka America Pharmaceutical, Inc."},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"NeurMedix","sponsor":"BioVie","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeurMedix \/ BioVie","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix \/ BioVie"},{"orgOrder":0,"company":"NeurMedix","sponsor":"BioVie","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeurMedix \/ BioVie","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix \/ BioVie"},{"orgOrder":0,"company":"NeurMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeurMedix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"vTv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ National Institutes of Health"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Thinkequity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Canaccord Genuity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Thinkequity"},{"orgOrder":0,"company":"Alzheon","sponsor":"Alerce Medical Technology Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series E Financing","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Alerce Medical Technology Partners","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Alerce Medical Technology Partners"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ National Institute on Aging"},{"orgOrder":0,"company":"Alzheon","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series D Financing","leadProduct":"Valiltramiprosate","moa":"Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Undisclosed"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Dextromethorphan","moa":"||Sigma-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"B. Dyson Capital Advisors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ B. Dyson Capital Advisors","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ B. Dyson Capital Advisors"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Simufilam","moa":"Filamin A","graph1":"Neurology","graph2":"Phase III","graph3":"Cassava Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Cassava Sciences \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Cassava Sciences \/ National Institute on Aging"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Neurology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Neurology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Tofersen","moa":"SOD1","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ION363","moa":"FUS","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ION363","moa":"FUS","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Abbhi Investments","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Autologous MSC-NTF Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Abbhi Investments","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Abbhi Investments"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Autologous MSC-NTF Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Israel Innovation Authority"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ Inapplicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ Inapplicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ Inapplicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"PrimeStreet Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ PrimeStreet Capital","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ PrimeStreet Capital"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chlorite","moa":"Macrophage","graph1":"Neurology","graph2":"Phase III","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neuvivo \/ Inapplicable"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Orphazyme","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Arimoclomol Citrate","moa":"HSF-1 pathway","graph1":"Neurology","graph2":"Phase III","graph3":"CytRx Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CytRx Corporation \/ Orphazyme","highestDevelopmentStatusID":"10","companyTruncated":"CytRx Corporation \/ Orphazyme"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"MPO","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"MPO","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"MPO","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"TINAPs","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Canaccord Genuity"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Canaccord Genuity"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"George Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ George Clinical","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ George Clinical"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Maryland Board of Public Works","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Financing","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Maryland Board of Public Works","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Maryland Board of Public Works"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Funding","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ National Institutes of Health"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Symbiosis II, LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Series D Financing","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Symbiosis II, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Symbiosis II, LLC"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Tottenham Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Merger","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Tottenham Acquisition","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Tottenham Acquisition"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Public Offering","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Undisclosed"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Tottenham Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Merger","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Tottenham Acquisition","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nanomedicine \/ Tottenham Acquisition"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Astellas Pharma"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reldesemtiv","moa":"Fast skeletal muscle troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"The ALS Association","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tirasemtiv","moa":"Troponin","graph1":"Neurology","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cytokinetics \/ The ALS Association","highestDevelopmentStatusID":"10","companyTruncated":"Cytokinetics \/ The ALS Association"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xiromed","sponsor":"IntelGenx","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Xiromed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Xiromed \/ IntelGenx","highestDevelopmentStatusID":"10","companyTruncated":"Xiromed \/ IntelGenx"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tanezumab","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Eli Lilly"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Donanemab","moa":"N3pG","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Evercore ISI","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Evercore ISI"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Evercore ISI","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Evercore ISI"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Engage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Alprazolam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Engage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Engage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Engage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Engage Therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Alprazolam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Engage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Engage Therapeutics \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Engage Therapeutics \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Tenacia Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ulixacaltamide","moa":"T type calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Tenacia Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Tenacia Biotechnology"},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"PGRN","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ GSK"},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Latozinemab","moa":"PGRN","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ GSK"},{"orgOrder":0,"company":"Alector","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Latozinemab","moa":"PGRN","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Alector","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Latozinemab","moa":"PGRN","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Licensing Agreement","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Immedica Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Immedica Pharma"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Agreement","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Immedica Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Immedica Pharma"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Public Offering","leadProduct":"Pegzilarginase","moa":"Arginase","graph1":"Neurology","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aeglea BioTherapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea BioTherapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Glibenclamide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Neurology","graph2":"Phase III","graph3":"Spine BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Spine BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spine BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Viscogliosi Bros.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Neurology","graph2":"Phase III","graph3":"Spine BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Spine BioPharma \/ Viscogliosi Bros.","highestDevelopmentStatusID":"10","companyTruncated":"Spine BioPharma \/ Viscogliosi Bros."},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Semnur Pharmaceuticals","sponsor":"Denali Capital Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Merger","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Semnur Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Semnur Pharmaceuticals \/ Denali Capital Acquisition Corp","highestDevelopmentStatusID":"10","companyTruncated":"Semnur Pharmaceuticals \/ Denali Capital Acquisition Corp"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"SNBL","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ SNBL","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Pharmaceuticals \/ SNBL"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tremeau Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rofecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Tremeau Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tremeau Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tremeau Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tremeau Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rofecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Tremeau Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tremeau Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tremeau Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Emergex Vaccines Holding","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Zolmitriptan","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Zosano Pharma \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pharma \/ Emergex Vaccines Holding"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Zosano Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Zosano Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Zosano Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Zosano Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eversana","sponsor":"Zosano Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Zolmitriptan","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Patch","sponsorNew":"Eversana \/ Zosano Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Eversana \/ Zosano Pharma"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Meloxicam","moa":"||COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Defender Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Defender Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Defender Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Defender Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"National Aeronautics and Space Administration","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Scopolamine Hydrobromide","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Defender Pharmaceuticals \/ National Aeronautics and Space Administration","highestDevelopmentStatusID":"10","companyTruncated":"Defender Pharmaceuticals \/ National Aeronautics and Space Administration"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tradipitant","moa":"NK-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tradipitant","moa":"NK-1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Inapplicable"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Evobrutinib","moa":"||BTK","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EMD Serono \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono \/ Merck & Co"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Osmotica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Osmotica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Osmotica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ImmuNext Inc","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"Frexalimab","moa":"CD40L","graph1":"Neurology","graph2":"Phase III","graph3":"ImmuNext Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmuNext Inc \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"ImmuNext Inc \/ Royalty Pharma"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ SVB Leerink"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Koneksa","sponsor":"old Sano","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Tolebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Koneksa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Koneksa \/ old Sano","highestDevelopmentStatusID":"10","companyTruncated":"Koneksa \/ old Sano"},{"orgOrder":0,"company":"Terran Biosciences","sponsor":"old Sano","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Tolebrutinib","moa":"BTK","graph1":"Neurology","graph2":"Phase III","graph3":"Terran Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Terran Biosciences \/ old Sano","highestDevelopmentStatusID":"10","companyTruncated":"Terran Biosciences \/ old Sano"},{"orgOrder":0,"company":"Viatris","sponsor":"Mapi Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","graph1":"Neurology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viatris \/ Mapi Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Mapi Pharma"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"MPO","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"MPO","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Verdiperstat","moa":"MPO","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"NOP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"NOP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Abuse Deterrent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocodone Bitartrate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Abuse Deterrent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Hydrocodone Bitartrate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neumentum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Phase III","graph3":"Neumentum","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neumentum \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neumentum \/ Inapplicable"},{"orgOrder":0,"company":"Neumentum","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Phase III","graph3":"Neumentum","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neumentum \/ Nuance Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Neumentum \/ Nuance Pharma"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eyenovia","sponsor":"William Blair","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Public Offering","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ William Blair","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/ William Blair"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"NOP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"NOP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cebranopadol","moa":"NOP receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Tris Pharma Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tris Pharma Inc \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Posiphen tartrate","moa":"TINAPs","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ TFS Trial Form Support","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ TFS Trial Form Support"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Thinkequity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Buntanetap","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Thinkequity"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Agent Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Solengepras","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Agent Capital","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Agent Capital"},{"orgOrder":0,"company":"Cerevance","sponsor":"Gates Frontier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Solengepras","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Gates Frontier","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Gates Frontier"},{"orgOrder":0,"company":"Cerevance","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Solengepras","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Google Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Google Ventures"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Solengepras","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Solengepras","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Denali Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BIIB122","moa":"LRRK2","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biogen \/ Denali Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ Denali Therapeutics"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Solengepras","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"NovaQuest Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Tavapadon","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ NovaQuest Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Therapeutics \/ NovaQuest Capital Management"},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Latozinemab","moa":"PGRN","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ GSK"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Midazolam","moa":"||GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Melt Pharmaceuticals \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Melt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Melt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABAA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Melt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SK Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Carisbamate","moa":"MAP2","graph1":"Neurology","graph2":"Phase III","graph3":"SK Life Science","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"SK Life Science \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SK Life Science \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zonisamide","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zonisamide","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longboard Pharmaceuticals \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longboard Pharmaceuticals \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"Longboard Pharmaceuticals \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Acasti Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Acasti Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Acasti Pharma"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Nantahala Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Nantahala Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Nantahala Capital Management"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"Eplontersen","moa":"ATTR protein","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"Eplontersen","moa":"ATTR protein","graph1":"Neurology","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ponesimod","moa":"S1P1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nimodipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Titan Partners Group"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Titan Partners Group"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Debamestrocel","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alzheon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Valiltramiprosate","moa":"Amyloid beta aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alzheon \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ Inapplicable"},{"orgOrder":0,"company":"BioVie","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bezisterim","moa":"NFkB\/ERK","graph1":"Neurology","graph2":"Phase III","graph3":"BioVie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioVie \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioVie \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Ensysce Biosciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Ensysce Biosciences \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Viatris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Meloxicam","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viatris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.070000000000000007,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Therapeutics \/ BVF Partners"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AbbVie Inc

                            U.S.A
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tavapadon

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie Reports Topline Results from Phase 3 TEMPO-2 Trial of Tavapadon in Parkinson’s

                            Details : CVL-751 (tavapadon) is the first and only D1/D5 receptor partial agonist, which is being studied as a once-daily treatment for patients with parkinson’s disease.

                            Product Name : CVL-751

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 09, 2024

                            Lead Product(s) : Tavapadon

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AbbVie Inc

                            U.S.A
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atogepant

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie Shares Data Supporting Long-Term Efficacy of Atogepant for Preventive Migraine

                            Details : Qulipta (atogepant) is an orally administered, CGRP receptor antagonist specifically developed for the preventive treatment of chronic and episodic migraine in adults.

                            Product Name : Qulipta

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 04, 2024

                            Lead Product(s) : Atogepant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AbbVie Inc

                            U.S.A
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tavapadon

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie Announces Positive Topline Results from Phase 3 for Tavapadon in Parkinson's

                            Details : CVL-751 (tavapadon) is the first and only D1/D5 receptor partial agonist, which is being studied as a once-daily treatment for patients with parkinson’s disease.

                            Product Name : CVL-751

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 26, 2024

                            Lead Product(s) : Tavapadon

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AbbVie Inc

                            U.S.A
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Foslevodopa,Foscarbidopa

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application

                            Details : ABBV-951 (foscarbidopa/foslevodopa) is a solution of carbidopa and levodopa prodrugs which targets dopamine receptor, it is being investigated for the treatment of motor fluctuations in patients with advanced parkinson's disease.

                            Product Name : ABBV-951

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 22, 2023

                            Lead Product(s) : Foslevodopa,Foscarbidopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AbbVie Inc

                            U.S.A
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atogepant

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Allergan Aesthetics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine

                            Details : Pivotal Phase 3 study evaluating QULIPTA™ (atogepant) in adult patients with chronic migraine meets primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo across the 12-week treatment per...

                            Product Name : Qulipta

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 03, 2022

                            Lead Product(s) : Atogepant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Allergan Aesthetics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AbbVie Inc

                            U.S.A
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Foslevodopa,Foscarbidopa

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 2022 MDS International Co...

                            Details : Researchers will present results from M15-736, active-controlled Phase 3 study, evaluating the continuous subcutaneous infusion of ABBV-951 (foslevodopa) with advanced Parkinson's disease and data from the ASPIRE study, evaluating BOTOX® for the treatme...

                            Product Name : ABBV-951

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 15, 2022

                            Lead Product(s) : Foslevodopa,Foscarbidopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AbbVie Inc

                            U.S.A
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atogepant

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Allergan Aesthetics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie to Present Extensive Data from its Migraine Portfolio at the 2022 American Headache Society® (AHS) Ann...

                            Details : QULIPTA™ (atogepant), as the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of episodic migraine.

                            Product Name : Qulipta

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 06, 2022

                            Lead Product(s) : Atogepant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Allergan Aesthetics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AbbVie Inc

                            U.S.A
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atogepant

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Allergan Aesthetics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expan...

                            Details : Atogepant (QULIPTA) would be the first gepant (oral calcitonin gene-related peptide [CGRP] receptor antagonist) approved for the broad indication of the preventive treatment of migraine, including episodic and chronic.

                            Product Name : Qulipta

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 26, 2022

                            Lead Product(s) : Atogepant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Allergan Aesthetics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AbbVie Inc

                            U.S.A
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Foslevodopa,Foscarbidopa

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for th...

                            Details : The submission is based on results from a Phase 3 trial for ABBV-951 (Foscarbidopa/Foslevodopa) demonstrating statistically significant improvement in "On" time without troublesome dyskinesia compared to oral immediate-release carbidopa/levodopa.

                            Product Name : ABBV-951

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 20, 2022

                            Lead Product(s) : Foslevodopa,Foscarbidopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AbbVie Inc

                            U.S.A
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Foslevodopa,Foscarbidopa

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Comp...

                            Details : ABBV-951 (Foslevodopa/Foscarbidopa) is a solution of levodopa and carbidopa prodrugs for continuous subcutaneous infusion that is being investigated for the treatment of advanced Parkinson's disease in patients whose motor symptoms are not controlled by ...

                            Product Name : ABBV-951

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 28, 2021

                            Lead Product(s) : Foslevodopa,Foscarbidopa

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth